Abstract
Background Homozygosity at HLA-I locus has been reported to be an unfavorable predictive biomarker of second-line or beyond immunotherapy in patients with different types of cancer. The linkage between HLA-I zygosity and survival in NSCLC patients treated with first-line immunotherapy with or without chemotherapy has not been reported.
Methods Next generation sequencing with HLA genotyping was performed for patients with advanced NSCLC treated with immune checkpoint inhibitors with or without chemotherapy as first-line (N = 29). Progression free survival was compared between HLA-I homozygous (defined as homozygosity in at least one locus A, B, or C) and heterozygous patients. Kaplan-Meier curves were built, and log-rank test was used.
Results Among 29 enrollees, 25 patients (86.2%) were HLA-I heterozygous and four patients (13.8%) were HLA-I homozygous. Treatment response was not available in five patients with HLA-I heterozygosity. Among 20 patients with HLA-I heterozygosity, five patients (20.0%) had partial response, 10 patients (50.0%) had stable disease, two patients (8.0%) had non-complete response/non-progressive disease, and three patients (12.0%) had progressive disease. Among four patients with HLA-I heterozygosity, one patient (25.0%) had partial response, one patient (25.0%) had stable disease, and two patients (50.0%) had progressive disease. The median progression free survival was not reached in heterozygous group and was 2.97 months in homozygous group (log-rank p = 0.68).
Conclusions We observed a trend toward an inverse association between HLA-I homozygosity and survival outcomes in patients with NSCLC treated with first-line therapy containing immunotherapy. Further prospective studies to validate such a relationship are warranted.
Competing Interest Statement
Young Kwang Chae: Research Funding: Abbvie, BMS, Biodesix, Lexent Bio, Freenome; Honoraria/Advisory Boards: Roche/Genentech, AstraZeneca, Foundation Medicine, Counsyl, Neogenomics, Guardant Health, Boehringher Ingelheim, Immuneoncia, Lilly Oncology, Merck, Takeda Pharmaceuticals. The other coauthors state NO financial affiliations/arrangements with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of this manuscript.
Funding Statement
Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our study was performed in accordance with Northwestern University guidelines/regulations and informed consent was obtained from all participants and/or their legal guardians. We received approval from Northwestern University Institutional Review Board and our study followed relevant guidelines and regulations.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Dongyup Lee: leego5000{at}gmail.com
Jonghanne Park: jonghanne.park{at}gmail.com
Horyun Choi: hrc.7177{at}gmail.com
Gahyun Gim: gahyungim{at}gmail.com
Sukjoo Cho: sjcho1989{at}gmail.com
Leeseul Kim: leeseul.kim88{at}gmail.com
Youjin Oh: yoojiin21{at}korea.ac.kr
Cyra Y Kang: cyrakang{at}gmail.com
Yeseul Kim: seul0990{at}gmail.com
Dean Tan: deantan2021{at}u.northwestern.edu
Pedro Antonio Hermida de Viveiros: pedro.viveiros{at}northwestern.edu
Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Data Availability
We attached supporting data and/or materials with our publication
Abbreviations
- ICIs
- immune check point inhibitors
- CTLA-4
- cytotoxic T lymphocyte-associated protein 4
- PD-1
- programmed cell death protein 1
- PD-L1
- programmed cell death protein ligand 1
- MSI
- microsatellite instability
- MMR
- mismatch repair
- HLA-I
- human leukocyte antigen class I
- OS
- overall survival
- TMB
- tumor mutational burden
- CR
- complete response
- PR
- partial response
- SD
- stable disease
- RECIST
- response evaluation criteria in solid tumors
- MDACC
- M. D. Anderson Cancer Center
- CM 012
- CheckMate 012
